ObjectiveTo evaluate the mean increase of anti-S IgG antibody titer between the basal, pre-booster level to the titer assessed 14 days after the booster dose of BNT162b2. Patients and MethodsThe RENAISSANCE study is an observational, longitudinal, prospective, population-based study, conducted on healthcare workers of Niguarda Hospital in Milan, Italy who received a BNT162b2 booster dose at least 180 days after their second dose or after positivity for SARS-CoV-2 and accepted to take part in the study. The RENAISSANCE study was conducted from January 1, 2021 through December 28, 2021. Findings1,738 subjects were enrolled among healthcare workers registered for the booster administration at our hospital. Overall, 0.4% of subjects were seronegative at the pre-booster evaluation, and 1 subject had a titer equal to 50 AU/ml: none of the evaluated subjects was seronegative after the booster dose. Thus, the efficacy of the booster in our population was universal. Mean increase of pre- to post-booster titer was more significant in subjects who never had SARS-CoV-2 (44 times CI 95% 42-46) compared to those who had it, before (33 times, CI 95% 13-70) or after the first vaccination cycle (12 times, CI 95% 11-14). Differently from sex, age and pre-booster titers affected the post-booster antibody response. Nevertheless, the post-booster titer was very similar in all subgroups, and independent of a prior exposure to SARS-CoV-2, pre-booster titer, sex or age. ConclusionOur study shows a potent universal antibody response of the booster dose of BNT162b2, regardless of pre-booster vaccine seronegativity.
Antibody Response to COVID-19 Booster Vaccination in Healthcare Workers / A. Pani, A. Romandini, A. Schianchi, M. Senatore, O.M. Gagliardi, G. Gazzaniga, S. Agliardi, T. Conti, P.A. Schenardi, M. Maggi, S. D'Onghia, V. Panetta, S. Renica, S.N. Molteni, C. Vismara, D. Campisi, M. Bertuzzi, S. Giroldi, L. Zoppini, M. Moreno, M. Merli, M. Bosio, M. Puoti, F. Scaglione. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 13:(2022), pp. 872667.1-872667.8. [10.3389/fimmu.2022.872667]
Antibody Response to COVID-19 Booster Vaccination in Healthcare Workers
A. Pani
Co-primo
;A. RomandiniCo-primo
;A. Schianchi;M. Senatore;O.M. Gagliardi;G. Gazzaniga;S. Agliardi;T. Conti;P.A. Schenardi;M. Maggi;S. D'Onghia;S. Renica;S.N. Molteni;C. Vismara;S. Giroldi;L. Zoppini;M. Moreno;F. ScaglioneUltimo
2022
Abstract
ObjectiveTo evaluate the mean increase of anti-S IgG antibody titer between the basal, pre-booster level to the titer assessed 14 days after the booster dose of BNT162b2. Patients and MethodsThe RENAISSANCE study is an observational, longitudinal, prospective, population-based study, conducted on healthcare workers of Niguarda Hospital in Milan, Italy who received a BNT162b2 booster dose at least 180 days after their second dose or after positivity for SARS-CoV-2 and accepted to take part in the study. The RENAISSANCE study was conducted from January 1, 2021 through December 28, 2021. Findings1,738 subjects were enrolled among healthcare workers registered for the booster administration at our hospital. Overall, 0.4% of subjects were seronegative at the pre-booster evaluation, and 1 subject had a titer equal to 50 AU/ml: none of the evaluated subjects was seronegative after the booster dose. Thus, the efficacy of the booster in our population was universal. Mean increase of pre- to post-booster titer was more significant in subjects who never had SARS-CoV-2 (44 times CI 95% 42-46) compared to those who had it, before (33 times, CI 95% 13-70) or after the first vaccination cycle (12 times, CI 95% 11-14). Differently from sex, age and pre-booster titers affected the post-booster antibody response. Nevertheless, the post-booster titer was very similar in all subgroups, and independent of a prior exposure to SARS-CoV-2, pre-booster titer, sex or age. ConclusionOur study shows a potent universal antibody response of the booster dose of BNT162b2, regardless of pre-booster vaccine seronegativity.File | Dimensione | Formato | |
---|---|---|---|
fimmu-13-872667.pdf
accesso aperto
Descrizione: Original Research
Tipologia:
Publisher's version/PDF
Dimensione
1.13 MB
Formato
Adobe PDF
|
1.13 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.